All In Biotech

Drug Trial Radar · NCT06038474

Descartes-08 for Patients With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Feb 12, 2024

Primary completion

Dec 1, 2026

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Cartesian TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • Descartes-08Drug

    Autologous T-cells expressing a chimeric antigen receptor directed to BCMA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE)Time frame: Day -59 to Day 50

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profound Research LLC

    Oceanside, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.